Abstracts tagged "T Cell"

Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 0646 • ACR Convergence 2022
Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway
Ruth Fernandez Ruiz¹, Ilona Nln², Jacqueline Paredes² and Timothy Niewold², ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: IFNα is a pathogenic factor in SLE. The PRKG1 rs7897633 variant has been previously identified as the top hit in European ancestry patients with…
Abstract Number: 1625 • ACR Convergence 2022
Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans
Blake Warner¹, Thomas Pranzatelli², Paola Perez², Daniel Martin², Shyh-Ing Jang², Kalie Dominick², Eiko Yamada², Kevin Byrd³, Quinn Easter⁴, A. Darise Farris⁵, Christopher Lessard⁵, Amanda Oliver⁶, Raquel Bartolome-Casado⁶, Zohreh Khavandgar¹, Sarthak Gupta⁷, Sarah Teichmann⁶, Alan Baer⁸ and John Chiorini², ¹National Institutes of Health, Bethesda, MD, ²NIDCR, Bethesda, MD, ³American Dental Association, Scientific Research Institute, Gaithersburg, MD, ⁴American Dental Association, Gaithersburg, MD, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wellcome Sanger Institute, Cambridgeshire, United Kingdom, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
Abstract Number: 1741 • ACR Convergence 2022
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
Leah Huey¹, Kylie Koney¹, Emily Vance¹, Chia-Feng Tsai², Rosalie K. Chu², Marina A. Gritsenko², Ellen Lee¹, Holly Rosenzweig¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA
Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
Abstract Number: 0044 • ACR Convergence 2022
Follistatin-like Protein 1 Alters T Cell Receptor Signaling Dynamics in Vitro, While Expression in Vivo Correlates with Disease and Deficiency Increases Acute Inflammation in a Mouse Model of Kawasaki Disease
Mateo Amezcua¹, Janice Huang¹, Miao Chen¹, Renee Escalona², Edward Dick² and Mark Gorelik¹, ¹Columbia University, New York, NY, ²Texas Biomedical Research Institute, San Antonio, TX
Background/Purpose: Kawasaki disease (KD) is an acute, febrile illness of childhood, associated with cardiac inflammation and vasculitis of coronary arteries and sometimes other medium sized…
Abstract Number: 0649 • ACR Convergence 2022
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
Marc Scherlinger¹, Wenliang Pan², Ryo Hisada¹, Milena Vukelic³, Masataka Umeda¹, Afroditi Boulougoura², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Ravi Kumar¹, Anatoly Dubnovitsky¹, Christina Gerstner¹, Niyaz Yoosuf², Sara Turcinov¹, Sanjay Boddul¹, Fredrik Wermeling¹, Lars Klareskog¹, Leonid Padyukov¹ and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Bioinvent International AB, Lund, Sweden
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…
Abstract Number: L07 • ACR Convergence 2021
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Niti Goel¹, Dulce Soler-Ferran², Monette Coutreau², Jorge Escobar³, Kate Courtemanche², Merrilee Needham⁴ and Steven Greenberg⁵, ¹Abcuro, Inc.; Duke University, Durham, NC, ²Abcuro, Inc., Newton, MA, ³Abcuro, Inc., Hayward, CA, ⁴Perron Institute, Murdoch University, Perth, Australia, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Garett Dunlap¹, Allison Billi², Feiyang Ma³, Johann Gudjonsson², J. Michelle Kahlenberg⁴ and Deepak Rao⁵, ¹Harvard University, Somerville, MA, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of California Los Angeles, Los Angelas, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
Abstract Number: 0967 • ACR Convergence 2021
Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy
Pascale Wehr¹, Ranjeny Thomas², Nishta Ramnoruth³, Swati Patel³, Jamie Rossjohn⁴ and Hugh Reid⁴, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²University of Queensland, Diamantina Institute, Brisbane, Australia, ³University Of Queensland, Brisbane, Australia, ⁴Monash University, Melbourne, Australia
Background/Purpose: The control of autoreactive T cells in an antigen-specific manner in autoimmune diseases is a major clinical research goal. Various regulatory immune signatures have…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1009 • ACR Convergence 2021
Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Amelie Jule¹, Maria Taylor², Kacie Hoyt³, Kevin Wei⁴, Maria Gutierrez-Arcelus¹, Siobhan Case¹, Mia Chandler¹, Margaret Chang², Ezra Cohen¹, Fatma Dedeoglu¹, Olha Halyabar¹, Jonathan Hausmann⁵, Melissa Hazen¹, Erin Janssen¹, Jeffrey Lo², Mindy Lo¹, Esra Meidan², Jordan Roberts¹, Mary Beth Son¹, Robert Sundel², Pui Lee⁶, Talal Chatila¹, Peter Nigrovic¹, Deepak Rao⁴ and Lauren Henderson⁷, ¹Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Virginia Tech Carilion School of Medicine, Roanoke, VA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Boston Children's Hospital, Newton, MA, ⁷Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement (< 5 joints) in the first 6 months of disease. A subgroup…
Abstract Number: 1012 • ACR Convergence 2021
Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
Serena Foo¹, Achilleas Floudas², Aisling O' Brien¹, Sharon Ansboro¹, Ronan Mullan³, Douglas Veale⁴, Emma MacDermott⁵, Derek Deely⁶, Charlene Foley⁶, Orla Killeen⁶ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ³Tallaght University Hospital, Dublin, Ireland, ⁴University College Dublin, Dublin, Ireland, ⁵Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ⁶Children's Health Ireland, Crumlin, Dublin, Ireland
Background/Purpose: Juvenile idiopathic arthritis (JIA) was thought to be the most common inflammatory arthritis in children. However an aggressive, erosive arthritis of little-known immunologic mechanism…
Abstract Number: 1438 • ACR Convergence 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Renan Vergara¹, Alex Chen¹, Jerry Chen¹, Marianne Riley¹, Luis Blancas-Mejia¹, Christie Mortales¹, Tania Berrocal¹, Tanu Priya¹, Marsha Mason¹, Kevin Yu¹, Olga Sharapova¹, Jorgen Nelson¹, Alfredo Quijano-Rubio¹, Thomas Linsky¹, Ryan Swanson¹ and Daniel-Adriano Silva², ¹Neoleukin Therapeutics, Inc., Seattle, WA, ²Formerly of Neoleukin Therapeutics, Inc., Seattle, WA
Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].